Eevia Health Plc – Interim Report Quarter 2 – 2021

The Board and CEO of Eevia Health Plc hereby present the Interim Report for the second quarter 2021, covering the period April 1^st through June 30^th, 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com

Significant events during the second quarter of 2021:

• Eevia experienced another reporting period with significant sales growth. Net sales for the second quarter of 2021 increased by over 250% compared to the same period in 2020. Net sales amounted to KEUR 1 491 (KEUR 423) or KEUR 1 369, excluding trading revenue[1]. Eevia’s strong revenue development during the quarter demonstrates the company’s ability to deliver on its long-term growth plan despite the temporary disruptions following the installation of new machinery.
• EBITDA for the period came in at KEUR -443 (KEUR -51) or KEUR -351 excluding transaction costs related to the IPO¹. EBITDA for the quarter was affected by non-recurring costs related to the installation of new machinery and the IPO.
• On June 29^th, Eevia was listed, and trading of shares started on Spotlight Stock Market in Sweden[2]. In connection with the listing, the company carried out an oversubscribed initial public share offer (IPO), which provided approximately MEUR 2,5 in new equity funding before transaction costs.
• Eevia completed a significant milestone in June, by entering into a multi-year sales agreement with a key international customer. The first three years of the sales agreement provides for minimum contracted sales of circa SEK 100 million. The new contract significantly increased the order reserve and, hence, created a strong base for operational planning for the next few years.
• The company successfully executed the initial phase of the current year’s two-step CAPEX plan, including the installation of a new evaporator, a thawing tank, a frozen block crusher, a new loading system, automation software, as well as other automation and process improvements. The installations were done in May and June, with completion of commissioning after the end of the quarter, in late July.
• In May, the company signed a KEUR 400 loan agreement with OP-Pohjola bank, that enabled a kick-start of certain critical investments in new capacity, prior the finalization of the IPO fundraising.  
• A new Board was elected in May. Johanna Panula, who has a long and merited management career from Novo Nordisk, entered the Board, improving the Board competence within pharmacology, nutrition, and regulatory affairs.

Significant events after 30 June 2021:

• The first phase of a planned capacity increase and plant improvement as communicated in the Investor memorandum was completed with commissioning of the equipment in late July.  The newly installed machines and technologies are working satisfactorily, with improved yield, productivity, and cost efficiency. These investments support the company's strong growth and strategic positioning, as communicated in the May 2021 information memorandum.

Comments from our CEO

Eevia continued its strong development in the second quarter this year. The period became heavily dominated by three main activities:

1. The final sales negotiations with a major US customer for a three-year sales agreement with sales value of SEK 100 million
2. The engineering, installation, and commissioning of several key new processing equipment in the first phase of a two-phase investment program for 2021; and
3. The preparations to list the company’s shares on Spotlight Stock Market in Stockholm.

The efforts behind each of these activities were significant and came on top of normal operational activities. The organization delivered well on all three fronts. The company signed a major SEK 100 million sales agreement on June 11th. We commissioned several new equipment during the quarter, which was finally completed late July. And, on June 29^th, the company was listed on Spotlight Stock Market, after a 400% subscribed IPO equity issue.

All three activities are key enablers to achieving the company’s long term business goals, and as CEO, I am both impressed and proud of the performance of the team, as well as the Board and our advisers. We came through and reached our targets, lifting the company to a new level while staking out a clear course for the next few years.

I was also happy to see that at the end of the quarter, production started to capitalize on the new equipment, with improved capacity, yields and gross margins starting to materialize! While the commissioning of the new equipment during this summer also involved certain operational disruptions in July, we are in a good position for the second half of 2021.

As we are experiencing an increasingly advanced and automated production set-up, we are also working to develop deeper technical competence in the company’s staff. Strong systems, competence and organizational agility are needed to run a more technically advanced manufacturing plant. Hence, developing the technical competence of our operators and shift leaders, through training and performance measurements, is a key target for the second half 2021.

The global market for nutraceutical ingredients is growing steadily. With the improved financial strength and new investments, Eevia is well placed to maintain its efforts to become a leading manufacturer globally of organically certified nutraceutical ingredients. We will continue these efforts in the second half of the year, capitalizing on our improved factory set-up by targeting new customers, while consolidating our relationship with existing clients.

With the improved financial strength and new investments, we are confident on delivering over MEUR 25 in turnover in 2024 with over 40% gross margin and EBITDA above 15% of turnover.

Wishing you a healthy and safe end of the summer.

Stein Ulve

CEO

Key ratios

The key ratios for January to June 2021 and 2020 are shown in the table below:

For more information, please contact: 

Kim Nurmi-Aro, CFO

kim@eeviahealth.com

Tel.: +358 504 44 0717

About Eevia

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are mostly wild harvested and key raw materials are harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B to dietary supplements and food brands globally, who utilize the products as ingredients in their consumer product formulas.

Eevia Health is fast-growing Finnish manufacturer of 100% organically certified plant extracts. Most of its raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36% anthocyanins) and pine bark extracts (70% oligomeric proanthocyanidins), are organically certified. 

Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw material harvest areas. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia is listed at Spotlight Stock Market with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.